mechanism of resistance. Hence, combination therapy with radiation and an inhibitor such as EPI-002 that antagonises both AR splice variant and full-length AR, may provide a new therapeutic approach for mCRPC.
INTRODUCTION AND OBJECTIVES:
The treatment of castration resistant prostate cancer (CRPC) has been complicated by recent development of multiple novel therapies, and there is an urgent need to develop biomarkers for precision medicine. We established a robust method to analyze AR status (copy number variations (CNV) and mutations) in plasma cell free DNA (cfDNA) by digital PCR and multiplex PCR based deep sequencing, and evaluated AR status in Japanese CRPC patients.
METHODS: AR CNV analysis by digital PCR was tested using genomic DNA (gDNA) from VCaP cell line and cfDNA from mouse xenografted with VCaP. AR mutation analysis by deep sequencing and digital PCR was tested using gDNA from LNCaP cell line and cfDNA from mouse xenografted with LNCaP. Next, we evaluated AR status in cfDNA from 92 CRPC patients. The association between AR status and clinicopathological factors was evaluated.
RESULTS: AR amplification was detectable in VCaP gDNA to 1.0% dilution, and also in VCaP xenograft cfDNA. AR mutation was detectable in LNCaP gDNA to 0.1% dilution by digital PCR, and to 1.0% dilution by deep sequencing. AR mutation was also detectable in LNCaP xenograft cfDNA. Of the 92 CRPC patients, AR amplification and mutation were detected in 45 (48.9%) and 19 (20.65%), respectively. Most of the mutations were in known hotspots on the ligand binding domain. Nine patients with AR mutation had multiple mutations. Overall, 54 (58.7%) of 92 patients had AR aberrations (amplification and/or mutation), and 10 had both AR amplification and mutation. In univariate analysis, clinicopathological factors associated with the presence of AR aberrations in cfDNA included higher PSA, higher cfDNA concentration and resistance to estramustine, enzalutamide, or abiraterone.
CONCLUSIONS: AR status in cfDNA could be analyzed by digital PCR and deep sequencing with high fidelity, and the rates of AR aberrations in our data was comparable to that in other reports. AR aberrarions in cfDNA might be a potential biomarker in CRPC.
Source of Funding: Astellas Pharma

MP29-06 INCREASED PRO-TUMORIGENIC PROPERTIES OF PROSTATE FIBROBLASTS IN AFRICAN AMERICAN MEN COMPARED TO CAUCASIANS
Marc Gillard, Chicago, IL; Susan Crawford, Charles Brendler, Evanston, IL; Donald Vander Griend, Chicago, IL; Omar Franco*, Evanston, IL INTRODUCTION AND OBJECTIVES: Despite advances in the diagnosis and treatment of prostate cancer (PCa), the incidence and death rate is still significantly higher for African Americans (AA) compared to Caucasian (CAU) men. cDNA microarray studies revealed that immune-inflammatory response, apoptosis and focal adhesion were differentially increased in AA vs. CAU prostate tumors. We have shown that chronic activation of pro-inflammatory cytokines and chemokines in prostate CAF increase tumor progression. However the biological effects of fibroblasts in the TME of AA patients has not been intensively studied due to the lack of suitable models. Here we isolated fibroblasts from human prostate tissues from AA patients with PCa and compared the biological effects on several PCa cell lines to evaluate the similarities and/or differences to those from CAU-derived fibroblasts METHODS: Prostate fibroblasts were isolated from patients AA (PrF-AA) and CAU (PrF-CAU) undergoing robotic assisted laparoscopic Vol. 199, No. 4S, Supplement, Saturday, May 19, 2018 THE JOURNAL OF UROLOGY â e367
